Prostate-Specific Antigen Test Market - By Test Type (Preliminary {Total, Complex, Free}, Confirmatory {PCA3, Biopsy}), By Application (Screening, Monitoring), By End-use (Hospitals, Specialty Clinics, Diagnostic Centers)

Description

List of Tables

Prostate-Specific Antigen Test Market size is set to expand at 8.3% CAGR from 2023 to 2032, driven by the ongoing shift towards comprehensive diagnostic approaches, including confirmatory tests. Of late, healthcare providers worldwide are increasingly embracing several holistic approaches to prostate health, such as integrating prostate-specific antigen (PSA) testing into broader diagnostic strategies. This shift is emphasizing the significance of early detection and personalized treatment plans, further surging the demand for PSA tests in preventive care.

With rising advances in scientific understanding of prostate health, researchers are focusing on developing innovative therapies and drugs. For instance, in November 2023, based on the outcomes of the Phase 3 EMBARK trial, Astellas Pharma and Pfizer received approval from the U.S. FDA for a supplemental New Drug Application for XTANDI® (enzalutamide), a promising treatment option for prostate cancer patients. The need for PSA tests is hence rising in tandem with such R&D efforts as accurate diagnostics are essential for monitoring treatment efficacy.

The PSA test industry is segmented into test type, application, end-use, and region.

Based on test type, the market size from the confirmatory segment is anticipated to gain 8.7% CAGR from 2023-2032. Confirmatory tests, including PCA3 and biopsy, are essential in providing accurate and conclusive results after an elevated PSA level is detected. The growing emphasis on precision medicine and personalized treatment plans is also enhancing the significance of confirmatory tests in prostate health diagnostics. Moreover, the growing adoption of comprehensive diagnostic approaches by healthcare providers will fuel the segment growth.

In terms of end-use, the prostate-specific antigen test industry from the hospitals segment is expected to witness 8.3% growth rate between 2023 and 2032. Hospitals serve as primary hubs for diagnostic procedures, including PSA testing, due to their comprehensive healthcare infrastructure. The rising incidence of prostate-related disorders and the increasing aging population are also contributing to the increasing demand for routine PSA screenings. Furthermore, the emphasis on early detection and cancer prevention programs within hospital settings will boost the segment growth.

Regionally, the Asia Pacific PSA test industry held sizable revenue share in 2022 and is poised to depict over 9% growth rate through 2032. Increasing awareness, the rising aging population, and the growing prevalence of prostate-related disorders are driving the demand for PSA testing in the region. Additionally, governments and healthcare organizations are actively promoting early detection and screening programs. Technological advancements in diagnostic procedures and the greater emphasis on men health will also contribute to the expanding adoption of PSA tests.

Product Code: 7136

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & working
1.3 Data collection
1.4 Base estimates & workings
1.5 Forecast calculations
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global prostate-specific antigen test market 360° synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Test type trends
- 2.1.4 Application trends
- 2.1.5 End-use trends

Chapter 3 Prostate-Specific Antigen Test Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of prostate cancer
  - 3.2.1.2 Growing geriatric population
  - 3.2.1.3 Technological advancements in PSA testing
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of PSA testing
3.3 Growth potential analysis
- 3.3.1 By test type
- 3.3.2 By application
- 3.3.3 By end-use
3.4 COVID- 19 impact analysis
3.5 Technology landscape
3.6 Regulatory landscape
3.7 Reimbursement scenario
3.8 Gap analysis
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Vendor matrix analysis, 2022
4.6 Strategy dashboard, 2022

Chapter 5 Prostate-Specific Antigen Test Market Size and Forecast, By Test Type, 2018-2032 (USD Million)

5.1 Key trends, by test type
5.2 Preliminary tests
- 5.2.1 Total prostate specific antigen test
- 5.2.2 Complex prostate specific antigen test
- 5.2.3 Free prostate specific antigen test
5.3 Confirmatory tests
- 5.3.1 PCA3 test
- 5.3.2 Trans-rectal ultrasound
- 5.3.3 Biopsy

Chapter 6 Prostate-Specific Antigen Test Market Size and Forecast, By Application, 2018-2032 (USD Million)

6.1 Key trends, by application
6.2 Prostate cancer screening
6.3 Prostate cancer monitoring

Chapter 7 Prostate-Specific Antigen Test Market Size and Forecast, By End-use, 2018-2032 (USD Million)

7.1 Key trends, by end-use
7.2 Hospitals
7.3 Diagnostic centers
7.4 Specialty clinics
7.5 Other end-users

Chapter 8 Prostate-Specific Antigen Test Market Size and Forecast, By Region, 2018-2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East & Africa

Chapter 9 Company Profiles

9.1 Abbott Laboratories Inc.
9.2 AdvaCare Pharma
9.3 Bayer AG
9.4 Bio-Rad Laboratories, Inc.
9.5 Beckman Coulter, Inc.
9.6 FUJIREBIO is an H.U. Group company.
9.7 GE HealthCare.
9.8 Abcam plc.
9.9 Lomina AG.
9.10 Laboratory Corporation of America Holdings